Share this article
BETHESDA, Md., April 13, 2021 /PRNewswire/
Noura Abul-Husn, MD, PhD, FACMG is the recipient of the ACMG Foundation for Genetic and Genomic Medicine s
2021 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award the Watson Award named for the American College of Medical Genetics and Genomics first and longstanding executive director, Dr. Michael Watson, FACMG. I am truly honored and delighted to receive this award from the ACMG Foundation, said Dr. Abul-Husn. I am deeply committed to growing an innovative program that translates genomic findings into improved patient care for diverse populations. We are delighted to announce that Dr. Noura Abul-Husn is the 2021 recipient of the Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award, said Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Foundation. Dr. Abul-Husn has been a pioneer in the application of genomics to improve health in diverse populations, helping to pave
Mount Sinai researchers have identified genetic and cellular mechanisms of Crohn's disease, providing new insights for future treatments that could offer.
new measures to predict bowel disease zimbabwestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zimbabwestar.com Daily Mail and Mail on Sunday newspapers.
Study discovers new measures to predict risk of bowel diseases ANI | Updated: Dec 27, 2020 23:01 IST
Washington [US], December 27 (ANI): Mount Sinai researchers claim to have discovered new measures to predict risk for inflammatory bowel diseases (IBD) including Crohn s disease and ulcerative colitis.
The study published in the research journal Gastroenterology shows that the polygenic risk scores, built using association data from multiple populations in Mount Sinai s multi-ethnic BioMe Biobank, maximized IBD predictions for every population in the biobank.
BioMe is a system-wide effort at Mount Sinai that is revolutionizing diagnosis and classification of diseases according to the patient s molecular profile.
The study showed that risk scores calculated from integrating data significantly improved predictions among individuals with European, Ashkenazi Jewish, and Hispanic ancestry in BioMe, as well as European individuals in the UK Bioban